A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes

Automated insulin delivery (AID) systems have shown benefits for patients with type 1 diabetes, but their role in managing insulin-treated type 2 diabetes remains unclear. This 13 week, multicenter, randomized trial assigned adults with insulin treated type 2 diabetes to receive AID or continue their pretrial insulin delivery method (control group), both with continuous glucose monitoring (CGM). The primary outcome was glycated hemoglobin levels at 13 weeks. Results showed a significant reduction in glycated hemoglobin levels in the AID group compared to the control group (0.6 percentage points; 95% CI, 0.8 to 0.4; P<0.001). The AID group also spent more time in the target glucose range (70–180 mg/dL) and had fewer hyperglycemia events, with no increase in hypoglycemia.

Automated insulin delivery (AID) systems have shown benefits for patients with type 1 diabetes, but their role in managing insulin-treated type 2 diabetes remains unclear. This 13 week, multicenter, randomized trial assigned adults with insulin treated type 2 diabetes to receive AID or continue their pretrial insulin delivery method (control group), both with continuous glucose monitoring (CGM). The primary outcome was glycated hemoglobin levels at 13 weeks. Results showed a significant reduction in glycated hemoglobin levels in the AID group compared to the control group (0.6 percentage points; 95% CI, 0.8 to 0.4; P<0.001). The AID group also spent more time in the target glucose range (70–180 mg/dL) and had fewer hyperglycemia events, with no increase in hypoglycemia.